4:29 a.m. Feb. 17, 2021
Vir and GSK Will Collaborate on Flu Therapy
GlaxoSmithKline and Vir Biotechnology will collaborate to develop the same type of treatments for flu that they have made for Covid-19.
1:00 a.m. Feb. 12, 2021
Let Employers Mandate Vaccines
Requiring a Covid-19 vaccination is like requiring hard hats or handwashing. Employers have the right to create a safe workplace.
3:30 p.m. Jan. 28, 2021
Qualtrics, Agrify Surge in Market Debuts. Ortho Clinical and Vinci Fall Below IPO Prices.
The companies make their entrance at a boom time for initial public offerings, with January on track to be the biggest opening month for new stocks in over 20 years.
5:08 a.m. Jan. 27, 2021
Vir Will Test Its Covid-19 Antibody With Eli Lilly’s, Sending Shares Up Again
The newly announced trial is the first effort to combine Covid-19 antibody therapies developed by different companies.
10:23 a.m. Jan. 6, 2021
Why France's blundering COVID vaccination campaign is seen as a Macron fiasco and failure of 'ruling elites'Only a few hundred French citizens have received a COVID-19 shot in the week since vaccines began to be rolled out in the European Union.
10:37 p.m. Dec. 23, 2020
Getting COVID-19 may protect you be protected against future infections, two new studies indicateThe results bode well for vaccines, which provoke the immune system to make antibodies — substances that attach to a virus and help it be eliminated.
4:21 p.m. Dec. 11, 2020
Coach and Kate Spade Will Drive Tapestry Stock Higher
And analysts report on Fiserve, Liberty Braves Group, and three other companies.
3:17 a.m. Dec. 10, 2020
- By Ciara Linnane
Gilead to acquire Germany's MYR GmbH for EUR1.15 billion in cash Gilead Sciences Inc. said Thursday it has agreed to acquire MYR GmbH, a German biotech, for 1.15 billion euros ($1.39 billion) in cash, plus a potential future milestone payment of up to 300 million euros. The milestone payment will be made upon FDA approval of MYR's hepcludex, a treatment for chronic HDV infection in adults with compensated liver disease that has won conditional approval from the European Medicines Agency. HDV is the most severe form of viral hepatitis. "Hepcludex is a first-in-class treatment for HDV that blocks viral entry into liver cells through binding to NTCP," Gilead said in a statement. "It is the first and currently the only medicine conditionally approved for HDV by the EMA, and MYR anticipates submission for accelerated approval in the United States in the second half of 2021." The drug has both orphan drug and breakthrough therapy designations from the FDA. Gilead is expecting the deal to enhance revenue, be neutral to EPS in the first two years and then modestly accretive. Gilead shares were slightly higher premarket, but have fallen 6% in the year to date, while the SPDR S&P Biotech ETF has gained 44% and the S&P 500 has gained 13.7%.
10:12 a.m. Dec. 9, 2020
Children probably won't get a COVID-19 vaccine before the next school year --- here's whyClinical trials for those 12 and older are just starting, and there haven't been any yet for those under 12.
5:11 a.m. Dec. 4, 2020
Vaccines and Approved Antibodies Dim Vir Biotechnology’s Covid Opportunity, Analyst Says
Competitors have already gotten emergency use authorizations from regulators and booked orders for their antibody treatments.
7:40 a.m. Nov. 25, 2020
- Associated Press
Argentine soccer great Diego Maradona dies at 60 Argentina’s president declared three days of national mourning for Maradona on WednesdayDiego Maradona, the Argentine soccer great who was among the best players ever and who led his country to the 1986 World Cup title before later struggling with cocaine use and obesity, has died. He was 60.
4:29 p.m. Nov. 1, 2020
Chinese Lender Lufax Raises $2.36 Billion in IPO. It’s a Broken Deal.
Shares of company backed by Ping An Insurance closed below the IPO price.
8:22 a.m. Oct. 29, 2020
COVID-19 immunity may only last a few months after infection, study indicatesResearchers find that the number of people in England with antibodies fell by 26% in the space of three months, though there is not yet scientific consensus on the longevity of COVID-19 antibodies.
1:06 p.m. Oct. 28, 2020
Gilead Sciences Benefits From Its Initial Quarter of Remdesivir Sales
The antiviral remdesivir came just in time for Covid-19 patients and for its developer, Gilead Sciences.
2:17 p.m. Oct. 23, 2020
Remdesivir Gets FDA Approval. What It Means for Gilead Stock and Vaccine Makers.
Until vaccines end the Covid pandemic, analysts expect billions of dollars in annual sales for treatments and other remedies.
11:22 a.m. Oct. 22, 2020
Gilead’s Sales Will Slip Even With Remdesivir
Citigroup analyst Mohit Bansal rates Gilead stock at Buy but lowered his target price to $75 from $80. He sees two more years of revenue decline.
12:30 a.m. Oct. 20, 2020
Gilead Defends Its Covid Treatment After WHO Study Finds It Ineffective
Gilead has criticized the WHO study findings and is seeking FDA approval for its antiviral remdesivir.
12:22 p.m. Oct. 16, 2020
Praxis Precision Pops 62% as Biotech IPO Party Continues
A dozen biotech companies have gone public this month, including four that listed on Friday.
6:32 a.m. Oct. 12, 2020
It Takes More Than Good Science to Defeat a Disease. Just Look at the Nobel Prize.
The Nobel in medicine was awarded for the discovery of the hepatitis C virus. The disease could be eliminated. Instead we’re treading water.
1:22 a.m. Oct. 12, 2020
Two Americans win Nobel prize in economics for auction theory advancesAmericans Paul R. Milgrom and Robert B. Wilson have won the Nobel Prize in economics for “improvements to auction theory and inventions of new auction formats.”
12:13 a.m. Oct. 9, 2020
World Food Program wins 2020 Nobel Peace PrizeThe Nobel Committee said that the coronavirus pandemic has added to the hunger faced by millions of people around the world and called on governments to ensure that WFP and other aid organizations receive the financial support necessary to feed them.
2:32 a.m. Oct. 5, 2020
3 win Nobel medicine award for hepatitis C virus discoveryAmericans Harvey J. Alter and Charles M. Rice, and British scientist Michael Houghton were awarded the Nobel Prize for Medicine or Physiology on Monday for the discovery of the hepatitis C virus.
6:04 a.m. Oct. 4, 2020
- By Jaimy Lee
Abbott exec: Why better COVID-19 tests may help the U.S. get back to normal John Hackett is a longtime executive at diagnostics company Abbott In less than seven months, Abbott Laboratories has introduced six COVID-19 tests, each a little different than the last, and that’s all part of the diagnostics company’s strategy to keep improving and enhancing tests that can detect current and past infections with the novel coronavirus.
4:13 a.m. Sept. 30, 2020
Regeneron’s Good News on Covid Antibodies Is Positive for Vaccines, Too
Late Tuesday, the company showed that infusions of its antibody cocktail cleared the coronavirus and Covid-19 symptoms from a group of test subjects.
5:28 a.m. Sept. 14, 2020
Gilead Bets Heavily in a Cancer Biotech Acquisition
Gilead is paying $21 billion for Immunomedics and its promising new cancer treatment. Wall Street’s unsure Gilead will earn back the steep acquisition price.
11:30 a.m. Sept. 13, 2020
Gilead reaches $21 billion deal for ImmunomedicsGilead Sciences Inc. will pay $21 billion to buy biotech Immunomedics Inc. and its prized breast-cancer drug, the company said Sunday, a sign of the value of the cancer-drugs business. Immunomedics has a market value of roughly $10 billion following a recent surge in its stock, meaning that Gilead is paying up to secure ownership of the company.
11:29 a.m. Sept. 13, 2020
AstraZeneca COVID-19 vaccine trials resumeAstraZeneca PLC said Saturday clinical trials for its experimental coronavirus vaccine have resumed in the U.K. after regulators concluded it was safe to do so, following a pause in studies globally after a person who received the vaccine had an unexplained illness.
11:01 a.m. Sept. 12, 2020
- By Cara Lombardo
Gilead near deal to buy Immunomedics for more than $20 billion Biotech drugmaker has a market value of roughly $10 billionGilead Sciences Inc. is nearing a deal to buy biotech Immunomedics Inc. and its prized breast-cancer drug for more than $20 billion.
10:23 a.m. Sept. 6, 2020
- By Quentin Fottrell
Sweden embraced herd immunity, while the U.K. abandoned the idea — so why do they both have high COVID-19 fatality rates? ‘Sweden’s prized herd immunity is nowhere in sight,’ according to an analysis in the Journal of the Royal Society of Medicine‘Sweden’s prized herd immunity is nowhere in sight,’ according to an analysis in the Journal of the Royal Society of Medicine.
3:00 p.m. Aug. 21, 2020
Robinhood’s Risks and Rewards
Letters on Robinhood, Federal Reserve market support, stock splits, Merck, and Amgen
1:29 p.m. Aug. 21, 2020
Why pooled testing could be a breakthrough in the fight against COVID-19What is pooled testing for COVID-19, and why does the U.S. need it?
3:05 a.m. Aug. 20, 2020
Barron’s Daily: Airbnb Picked a Terrible Time to File for an IPO
Kamala Harris accepts Democratic nomination for vice president, Regeneron and Roche team up on antibody treatment, Apple hits $2 trillion milestone, and other news to start your day.
11:58 p.m. Aug. 9, 2020
- By Sherri Snelling
Could flu vaccines lower your risk of Alzheimer’s? Research sheds new light Two studies released at the Alzheimer’s Association conference indicate a possible connection between flu and pneumonia shots with reducing or delaying cognitive declineThe studies show ‘vaccines are strongly associated with lower prevalence of dementia,’ says one scientist.
12:16 a.m. Aug. 4, 2020
- By Meera Jagannathan
'We do not want to return to a time when parents had to worry their infant could die of meningitis': Some kids still await routine vaccinations during COVID‘We do not want to return to a time when parents had to worry their infant could die of meningitis — especially when we have a vaccine to prevent it.’
7:46 a.m. Aug. 3, 2020
Gilead Will Get a Boost From Covid-Treatment Sales, Citi Says
Sales of its Covid-19 treatment could be worth more than $3 billion this year for Gilead Sciences, Citigroup’s Mohit Bansal says.
1:13 a.m. July 31, 2020
- By Jaimy Lee
Gilead swings to a big loss on acquisition expense, stock falls after earnings and revenue miss The drugmaker expects to produce more than 2 million courses of COVID-19 treatment remdesivir by the end of the yearShares of Gilead Sciences Inc. fell more than 1% in after-hours trading Thursday after the drugmaker reported that it swung to a large loss during the second quarter and missed estimates even after adjusting for an acquisition.
7:01 a.m. July 25, 2020
Questions About Covid-19 Pricing Arise
Concerns over drug prices show new signs of life in Washington
4:58 a.m. July 23, 2020
Moderna’s Vaccine Will Likely Be Approved, Analyst Says. Why the Stock Is ‘Unattractive.’
SVB Leerink analyst Mani Foroohar began coverage of the stock with a Market Perform rating.
1:11 a.m. June 30, 2020
- By Jaimy Lee
Gilead’s coronavirus drug will cost $2,340 — which sounds expensive, but here’s why it’s not The drugmaker’s decision to price remdesivir below expectations could be a ‘promising sign’ of how much other COVID-19 treatments will cost, said one expertGilead Sciences Inc.’s COVID-19 drug remdesivir will cost much less than Wall Street analysts had predicted in a move that likely points to a more measured, responsible approach to the pharmaceutical pricing of treatments and vaccines during the pandemic.
9:06 a.m. June 29, 2020
- By Jaimy Lee
Race for a COVID-19 vaccine has drug makers scaling up manufacturing — before one is developed ‘People, companies are starting to plan to make doses even before, you know, the vaccine works,’ Dr. Anthony Fauci said Tuesday on Capitol HillInovio Pharmaceuticals Inc. has yet to share results from the Phase 1 trial for its COVID-19 vaccine candidate, but has already received millions of dollars in funding to scale up manufacturing capacity.